List of Excipients in API atovaquone and proguanil hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing atovaquone and proguanil hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | CELLULOSE, MICROCRYSTALLINE | |
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | FERRIC OXIDE RED | |
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | HYPROMELLOSE | |
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | |
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | MAGNESIUM STEARATE | |
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | POLOXAMER 188 | |
| GlaxoSmithKline LLC | MALARONE | atovaquone and proguanil hydrochloride | 0173-0675 | POLYETHYLENE GLYCOL 400 | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing atovaquone and proguanil hydrochloride
Detailed excipient profiles for atovaquone and proguanil hydrochloride
Excipient focus: CELLULOSE, MICROCRYSTALLINE
atovaquone and proguanil hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
atovaquone and proguanil hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
atovaquone and proguanil hydrochloride drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
atovaquone and proguanil hydrochloride drug variants not containing CROSPOVIDONE
Excipient focus: FERRIC OXIDE RED
atovaquone and proguanil hydrochloride drug variants containing FERRIC OXIDE RED
atovaquone and proguanil hydrochloride drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
atovaquone and proguanil hydrochloride drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
atovaquone and proguanil hydrochloride drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: FERROSOFERRIC OXIDE
atovaquone and proguanil hydrochloride drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
atovaquone and proguanil hydrochloride drug variants not containing FERROSOFERRIC OXIDE
Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
atovaquone and proguanil hydrochloride drug variants containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
atovaquone and proguanil hydrochloride drug variants not containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
Excipient focus: HYPROMELLOSE
atovaquone and proguanil hydrochloride drug variants containing HYPROMELLOSE
atovaquone and proguanil hydrochloride drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2910
atovaquone and proguanil hydrochloride drug variants containing HYPROMELLOSE 2910
atovaquone and proguanil hydrochloride drug variants not containing HYPROMELLOSE 2910
Excipient focus: LACTOSE MONOHYDRATE
atovaquone and proguanil hydrochloride drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
atovaquone and proguanil hydrochloride drug variants not containing LACTOSE MONOHYDRATE
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
atovaquone and proguanil hydrochloride drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
atovaquone and proguanil hydrochloride drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
Excipient focus: MAGNESIUM STEARATE
atovaquone and proguanil hydrochloride drug variants containing MAGNESIUM STEARATE
atovaquone and proguanil hydrochloride drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 188
atovaquone and proguanil hydrochloride drug variants containing POLOXAMER 188
atovaquone and proguanil hydrochloride drug variants not containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
atovaquone and proguanil hydrochloride drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
atovaquone and proguanil hydrochloride drug variants not containing POLYETHYLENE GLYCOL
Excipient focus: POLYETHYLENE GLYCOL 400
atovaquone and proguanil hydrochloride drug variants containing POLYETHYLENE GLYCOL 400
atovaquone and proguanil hydrochloride drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 8000
atovaquone and proguanil hydrochloride drug variants containing POLYETHYLENE GLYCOL 8000
atovaquone and proguanil hydrochloride drug variants not containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
atovaquone and proguanil hydrochloride drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
atovaquone and proguanil hydrochloride drug variants not containing POVIDONE
Excipient focus: POVIDONE K30
atovaquone and proguanil hydrochloride drug variants containing POVIDONE K30
atovaquone and proguanil hydrochloride drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | atovaquone and proguanil hydrochloride | 0378-4160 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
atovaquone and proguanil hydrochloride drug variants containing SILICON DIOXIDE
atovaquone and proguanil hydrochloride drug variants not containing SILICON DIOXIDE
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
atovaquone and proguanil hydrochloride drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
atovaquone and proguanil hydrochloride drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
Excipient focus: TITANIUM DIOXIDE
atovaquone and proguanil hydrochloride drug variants containing TITANIUM DIOXIDE
atovaquone and proguanil hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
